Castration-resistant Prostate Cancer Clinical Trials in Montreal, Quebec
12 recruitingMontreal, Quebec, Canada
Showing 1–12 of 12 trials
Recruiting
Phase 3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Metastatic Castration-resistant Prostate Cancer
Pfizer900 enrolled240 locationsNCT06629779
Recruiting
Phase 3
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Amgen750 enrolled134 locationsNCT07213674
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled329 locationsNCT06136650
Recruiting
Phase 2
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Hoffmann-La Roche100 enrolled32 locationsNCT07287150
Recruiting
Phase 3
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Metastatic Castration-resistant Prostate Cancer
AstraZeneca670 enrolled90 locationsNCT07611110
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled282 locationsNCT06764485
Recruiting
Phase 1
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Advanced Metastatic Castration-resistant Prostate CancerProstate Specific Membrane Antigen (PSMA) Expression
Bayer198 enrolled35 locationsNCT06217822
Recruiting
Phase 3
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
Metastatic Prostate CancerMetastatic Castration-resistant Prostate Cancer
Canadian Cancer Trials Group236 enrolled14 locationsNCT06439225
Recruiting
Phase 1
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
AbbVie230 enrolled26 locationsNCT06318273
Recruiting
Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Colorectal, CancerGastric CancerBiliary Tract Cancer+4 more
AstraZeneca454 enrolled95 locationsNCT05489211
Recruiting
Phase 3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Metastatic Castration-resistant Prostate Cancer
Amgen675 enrolled164 locationsNCT06691984
Recruiting
Phase 2
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
Metastatic Prostate CancerCastration-resistant Prostate Cancer
Sir Mortimer B. Davis - Jewish General Hospital66 enrolled10 locationsNCT04070209